REN and type 2 diabetes mellitus: These studies have indicated that finerenone impacts cardiovascular outcomes in patients with type 2 diabetes and CKD in a background of maximal renin-angiotensin system blockade therapy, primarily due to a reduction in hospitalization due to heart failure.